Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
Go back to Strongbridge Biopharma plc Announces Positive Top-Line Results from the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome| (NASDAQ: SBBP) | Delayed: 2.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.00 | 52 Week High | $7.99 | |||
| Open | $0.11 | 52 Week Low | $3.30 | |||
| Day High | $2.00 | P/E | N/A | |||
| Day Low | $2.00 | EPS | $0.00 | |||
| Volume | 21,283,258 | |||||
